Inspyr Therapeutics

Inspyr Therapeutics is a development-stage company dedicated to developing targeted cancer therapies, with a focus on breast cancer, prostate cancer, bladder cancer, and kidney cancer. The company is involved in the discovery and development of prodrug cancer therapeutics. Prodrugs are inactive precursors of drugs that are converted into their active form only at the tumor site. Its prodrug development candidates include G-202, which is in Phase I clinical trials and targets the vasculature of various solid tumors, as well as G-114, G-115, and Ac-GKAFRR-L12ADT, which are used in preclinical animal models for the treatment of prostate cancer.